MDG Medicalgorithmics S.A.
Medicalgorithmics S.A. provides AI-powered and noninvasive solutions for cardiac diagnostic in Poland, the United States, and internationally. It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an AI-Driven lightweight wireless holter monitor; DeepRhythmAI, a hardware-agnostic cloud-based software that leverages cutting-edge AI technology to detect, classify, analyze, and report ECG data; and DeepRhythmAI, a set of algorithms for heart rhythm analysis that integrates into third-party software and devices. The company also provides virtual cardiac stress test (VCAST), an AI-based medical system developed for non-invasive, clinical quantitative, and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. In addition, the company engages in research and development services, including algorithm development, clinical studies, software development, consulting services, and medical hardware development; and end-to-end ECG Monitoring for clinical trials. Medicalgorithmics S.A. company was incorporated in 2005 and is headquartered in Warsaw, Poland.…
Industry Peers
Medical DevicesKey Statistics
About Medicalgorithmics (WSE: MDG)
›
Medicalgorithmics (WSE: MDG) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 109 employees.
The shares were at 20.65 PLN on 19 November 2026, down 36.1% over 52 weeks. Its 52-week range is 20.20 PLN to 38.65 PLN: the price is 46.6% below the high and 2.2% above the low.
Its market capitalisation is 215.86M PLN.
Medicalgorithmics reports return on equity of -18.1%, an operating margin of -10.7% and revenue up 55.7% year over year.
Its debt exceeds its cash by 24.38M PLN, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 40.85 PLN is 97.8% above the current price.